Today: 9 April 2026
Subscribe
Browse Category

NYSE:HIMS 3 July 2025 - 18 November 2025

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

HIMS Stock Today (November 18, 2025): Buyback, GLP‑1 Price War and What It Means for Hims & Hers Investors

Hims & Hers shares closed Monday at $35.58, down 3.79%, and traded around $35.00 pre-market Tuesday after announcing a new $250 million share repurchase program. The company faces pressure from a recent sell-off and rising competition in the weight-loss drug market. Shares remain up about 70% over the past year but have dropped 29% in the last month.
18 November 2025
·
Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update

Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update

Hims & Hers Health shares fell about 7–8% to $36.05 Friday after launching its new Labs diagnostic platform with Quest Diagnostics. The company’s market cap stands near $8.2 billion. Labs offers nationwide blood testing and health monitoring through annual subscriptions. The stock remains up roughly 43% year-to-date but trades well below its 52-week high.
14 November 2025
··
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir shares rose after Q3 results beat estimates and the company raised its outlook for a third straight quarter, citing surging AI platform demand. Hims & Hers stock jumped 7% post-market as it entered talks to offer Novo Nordisk’s Wegovy, despite mixed earnings. Sarepta plunged over 20% after a key Duchenne drug trial failed its main goal. Sanmina soared 18% on a strong earnings beat and guidance far above Wall Street forecasts.
4 November 2025
·······
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 November 2025
···
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Hims & Hers Health launched a menopause and perimenopause care program on its Hers platform Oct. 15, triggering a one-day stock surge of up to 16%. Shares quickly reversed, falling 11% to around $52–53 by Oct. 17. The company aims for $1 billion annual revenue in women’s health by 2026. Analysts remain divided, citing high valuation and volatile trading despite rapid revenue growth.
17 October 2025
·
Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Hims & Hers shares jumped 16% on Oct. 15 after launching a menopause care program, trading near $62.80 on Oct. 16, up 7% for the day. The stock has more than doubled in 2025, far outpacing rivals like Teladoc. Regulatory scrutiny from the FDA and FTC triggered brief sell-offs in September. Analyst sentiment remains cautious, with most price targets in the high $30s despite recent gains.
16 October 2025
··
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers Stock Soars on New Menopause Care Expansion – What Comes Next?

Hims & Hers shares surged nearly 13% on Oct. 15 after launching a menopause/perimenopause program on its Hers telehealth platform. The stock traded around $61 by mid-day with 29 million shares exchanged. The company now serves 2.4 million subscribers and reported Q2 revenue of $545 million, up 73% year-over-year. Analysts remain cautious, with most rating the stock Hold or Sell.
15 October 2025
·
Digital Health & Telemedicine Industry Update (June–July 2025)

Digital Health & Telemedicine Industry Update (June–July 2025)

DispatchHealth and Medically Home merged in June 2025, creating one of the largest high-acuity hospital-at-home providers under the DispatchHealth name. Novo Nordisk ended its Wegovy deal with Hims & Hers Health in late June over compounded drug concerns, causing Hims & Hers shares to drop 30%. Teladoc Health shifted strategy after acquiring Catapult Health and UpLift earlier in the year.
3 July 2025
····
1 2

Stock Market Today

  • Stocks Slip as US-Iran Ceasefire Optimism Wanes; Oil Prices Surge
    April 9, 2026, 12:18 PM EDT. Stocks dipped as S&P 500, Dow Jones, and Nasdaq 100 indexes retreated following fading optimism over a US-Iran ceasefire. June E-mini futures reflected this softening trend. Crude oil jumped over 5%, driven by the Strait of Hormuz blockade and escalating tensions from Israeli-Lebanon clashes, threatening the fragile truce. Both the US and Iran accused each other of ceasefire breaches, complicating Saturday's talks. U.S. economic data disappointed, with rising unemployment claims, weaker personal income and spending, and downwardly revised Q4 GDP growth adding pressure. Oil tanker restrictions amplified shipping delays, with over 1,000 vessels waiting near the strait, historically a key global energy transit route. Markets price in only a 2% chance of a Federal Reserve rate hike in late April, while overseas shares also fell, weighing on sentiment.

Latest article

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

9 April 2026
Palantir Technologies dropped about 7% Thursday after Michael Burry said Anthropic was overtaking it in enterprise AI, putting Palantir on track to lose $34 billion in market value. Anthropic reported its annualized revenue run rate had surged past $30 billion and launched new AI tools for businesses. Nearly one in four businesses on Ramp now pays for Anthropic, according to Ramp data. Palantir’s stock still trades at 395 times earnings.
Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

9 April 2026
Salesforce shares hit a new 52-week low Thursday, dropping 3.7% to $169.76 despite reporting 12% revenue growth and strong demand for its AI products. The broader software sector continued to slide, with the S&P 500 software and services index down about $1 trillion since January. Salesforce raised its buyback authorization to $50 billion and increased its dividend to 44 cents a share.
ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

9 April 2026
ServiceNow shares dropped 5.1% to $92.45 by 10:20 a.m. EDT Thursday, hitting a new 52-week low after analysts at Stifel, BTIG, and Goldman Sachs cut price targets citing weak federal spending and limited 2026 growth. The company announced it will integrate AI, data, security, and governance into all products ahead of first-quarter results due April 22.
SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

9 April 2026
Tesla is developing a smaller, cheaper electric SUV to be built first in Shanghai, sources said. The new model would cost less than the Model 3 and be smaller than the Model Y. Tesla produced 408,386 vehicles but delivered only 358,023 in Q1, as U.S. demand weakened and competition increased. Shares fell 0.8% Thursday.
Go toTop